INTRODUCTION {#s1}
============

Pterygium is a common ocular surface growth disorder originating in the conjunctiva and extending to the cornea \[[@R1]\]; its incidence ranges from 0.7% to 31% \[[@R2], [@R3]\]. The standard treatment for pterygium is surgical excision, but the recurrence rate after surgery can be as high as 24%--89%, which compromises outcomes \[[@R4]\]. Farid et al. \[[@R5]\] reported that the average time to recurrence was 3.13 months. Based on the simple excision of pterygium, multiple strategies and techniques have been developed to reduce the high rate of pterygium recurrence, including limbal conjunctival autograft \[[@R6]\], human amniotic membrane grafting \[[@R7]\], beta-irradiation \[[@R8]\], stem cell transplantation \[[@R9]\], mitomycin-C \[[@R10]\] and fibrin glue (FG) \[[@R11], [@R12]\]. However, severe complications might be induced by pterygium surgery, such as autograft dehiscence and corneal lesions \[[@R13], [@R14]\]. Conjunctival or limbal conjunctival autograft are suggested to be the best treatment with a low recurrence rate ranging from 1.9% to 5.3%, and high safety according to some studies \[[@R15]--[@R18]\]. Furthermore, they have been demonstrated to be more effective at treating recurrent pterygium than other methods \[[@R19]\].

Traditionally, the most common method of conjunctival autograft fixation in pterygium surgery is the use of absorbable or non-absorbable sutures. However, this prolongs surgical duration and is associated with several complications, such as sub-conjunctival hemorrhage, proliferative granuloma, and corneal epitheliopathy \[[@R20], [@R21]\]. In 2004, Koranyi et al. \[[@R22]\] reported that the use of FG instead of sutures when attaching the conjunctival transplant in pterygium surgery causes significantly less postoperative pain and significantly shortens surgical duration. Therefore, FG as an alternative to sutures for conjunctival autograft fixation, has been applied in pterygium surgery.

FG contains equal amounts of two components: aprotinin, along with a thrombin CaCl~2~ solution, and fibrinogen mixed with factor XIII \[[@R23]\]. Although many clinical trials have compared the efficacy of FG versus sutures in pterygium surgery, the results have not always been consistent. Moreover, the conclusion of a single clinical trial is limited by its relatively small sample size, shorter duration of follow-up, and difference in patient populations and surgical technique compared with other studies. Furthermore, the extent to which differences in the study region, patients and inconsistencies in case and control inclusion criteria between studies explain the conflicting outcomes is unknown. Therefore, meta-analysis provides a useful tool for the measurement of heterogeneity \[[@R24]\]. In fact, two published meta-analyses compared the efficacy of FG versus sutures in pterygium surgery in 2011. Pan et al. \[[@R25]\] included seven RCTs \[[@R13], [@R22], [@R23], [@R26]--[@R29]\] involving 342 participants with 366 eyes, and Shi et al. \[[@R30]\] included 366 eyes from seven RCTs \[[@R13], [@R22], [@R26]--[@R29], [@R31]\]. Additionally, Shi et al. \[[@R30]\] did not assess the quality of the included studies. Furthermore, only the recurrence rate, complication rate, and surgical duration were measured in these previous meta-analyses, stratified analyses including region, sample size, duration of follow-up, and suture material were not conducted.

Additional clinical trials have since been conducted to compare the efficacy of FG versus sutures in pterygium surgery. Therefore, we performed an updated meta-analysis to further explore the association between the application of FG in pterygium surgery and the recurrence rate, complication rate, and surgical duration. A greater number clinical trials with larger sample sizes were included in our meta-analysis, and several stratified analyses including region, study type, suture material, sample size, follow-up time, and study quality score were conducted.

RESULTS {#s2}
=======

Literature search and characteristics of selected studies {#s2_1}
---------------------------------------------------------

Initially, 105 relevant studies were obtained through a literature search. We excluded 51 studies after a review of the abstracts because they were meta-analyses, abstracts, summary studies, or not clinical trials, and 22 studies were excluded because they did not compare between FG versus suture. We then conducted a full-text review of the remaining 32 articles. Seven studies were excluded because these did not use conjunctival autograft in pterygium surgery, and one due to lack of available data \[[@R3]\]. Therefore, 24 clinical trials \[[@R5], [@R13], [@R14], [@R20]--[@R23], [@R26]--[@R29], [@R31]--[@R43]\] comparing the efficacy of FG versus sutures for limbal conjunctival autograft fixation in pterygium surgery were selected for inclusion in the meta-analysis. The flow chart of candidate study selection is summarized in Figure [1](#F1){ref-type="fig"}.

![Flow chart showing the selection process for the included studies](oncotarget-08-41487-g001){#F1}

A total of 1839 eyes in 24 included clinical trials published from 2004 to 2015 were enrolled in this meta-analysis. Among the 24 clinical trials, 16 studies were randomized controlled trials (RCTs), and the remaining eight trials were non-RCTs, including retrospective studies and simple comparative studies. Seventeen of the studies included Asian participants and seven included non-Asian participants. The sample sizes of these clinical trials ranged from 17 to 461, and the mean patient age ranged from 40.1 to 63 years. The sutures applied in the suture group included vicryl and nylon (i.e., absorbable and non-absorbable sutures). The duration of follow-up ranged from 2 to 29 months. Jadad score was applied to assess the quality of the included RCTs; nine RCTs obtained a score of at least 3 indicating high-quality studies, while seven RCTs scored 2 indicating low-quality studies. The characteristics and quality score of the selected clinical trials are summarized in Table [1](#T1){ref-type="table"}.

###### The characteristics and quality score of the selected clinical trials

  Author                         Year   Country       Study type   Type of suture   Age (FG/SE)   Sample size   Recurrence (%)   Complications (%)   Operating time (FG/SE)   Follow-up (month)   Jadad score                                           
  ------------------------------ ------ ------------- ------------ ---------------- ------------- ------------- ---------------- ------------------- ------------------------ ------------------- ------------- ------- ------- ------- ------- ------- ---
  Koranyi G \[[@R22]\]           2004   Sweden        RCT          Vicryl 7-0       44/48         20            23               2(10%)              4(18%)                   0(0%)               0(0%)         9.70    2.48    18.50   6.6     6.00    3
  Uy HS \[[@R13]\]               2005   Philippines   RCT          nylon 10-0       45/45         11            11               0(0%)               0(0%)                    1(10%)              1(10%)        27.80   1.00    67.00   3.60    12.00   5
  Jiang J \[[@R23]\]             2008   China         RCT          nylon 10--0      57/57         20            20               1(5%)               2(10%)                   3(15%)              1(5%)         17.90   2.60    31.80   3.3     6.00    2
  Ozdamar Y \[[@R28]\]           2008   Turkey        RCT          Vicryl 8-0       42.6/42.6     12            12               0(0%)               0(0%)                    0(0%)               0(0%)         /       /       /       /       12.00   4
  Karalezli A \[[@R27]\]         2008   Turkey        RCT          Vicryl 8-0       53.4/58.5     25            25               1(4%)               3(12%)                   7(28%)              12(48%)       15.70   2.40    32.50   6.70    12.00   3
  Farid M \[[@R5]\]              2009   USA           RCT          Vicryl 8-0       47.3/52.2     27            20               1(3.7%)             4(20%)                   /                   /             /       /       /       /       12.00   3
  Coral-Ghanem R \[[@R33]\]      2010   Brazil        RCT          Vicryl 8-0       42.6/49.3     106           58               12(11.32%)          15(26%)                  /                   /             /       /       /       /       12.00   3
  Malik VK \[[@R34]\]            2010   India         RCT          Vicryl 8-0       60.08/60.36   25            25               1(4%)               3(12%)                   2(8%)               7(28%)        18.24   2.20    26.60   1.93    13.60   2
  Cagatay HH \[[@R21]\]          2014   Turkey        RCT          Vicryl 8-0       52.08/53.75   53            53               1(1.89%)            4(8%)                    5(10%)              7(14%)        /       /       /       /       6.00    3
  Vichare N \[[@R37]\]           2013   India         RCT          nylon 10--0      46.8/49.5     30            30               1(3.33%)            3(10%)                   /                   /             34.43   4.94    50.93   4.96    13.00   3
  Sati A \[[@R38]\]              2014   India         RCT          Vicryl 8-0       40.1/40.9     30            30               2(6.67%)            3(10%)                   2(7%)               0(0%)         15.50   1.20    27.63   1.63    6.00    3
  Cui B \[[@R31]\]               2009   China         RCT          nylon 10-0       52/55         20            20               0(0%)               0(0%)                    0(0%)               0(0%)         20.50   3.60    42.80   4.5     6.00    2
  Lei QF \[[@R41]\]              2015   China         RCT          nylon 10-0       52/50         30            30               1(3.33%)            3(10%)                   /                   /             24.50   6.50    35.20   5.4     6.00    2
  Hu JF \[[@R43]\]               2012   China         RCT          Vicryl 8-0       55.45/53.42   46            43               2(4.35%)            6(14%)                   /                   /             30.65   9.43    46.56   10.24   24.00   2
  Hu QM \[[@R42]\]               2014   China         RCT          nylon 10-0       52.14/53.14   40            36               /                   /                        /                   /             18.33   0.50    39.13   1.02    9.00    2
  Liu H \[[@R40]\]               2013   China         RCT          nylon 10-0       /             30            30               0(0%)               0(0%)                    1(4%)               0(0%)         20.32   17.35   28.79   19.53   6.00    2
  Koranyi G \[[@R14]\]           2005   Sweden        non RCT      Vicryl           44/48         258           123              14(5.43%)           17(14%)                  13(6%)              11(9%)        /       /       /       /       2.00    /
  Miranda-Rollón MD \[[@R32]\]   2009   Spanish       non RCT      Vicryl 8-0       59.8/59.8     8             9                1(12.5%)            0(0%)                    1(13%)              4(45%)        /       /       /       /       29.00   /
  Hall RC \[[@R26]\]             2009   New Zealand   non RCT      Vicryl 8-0       47.8/49.8     24            23               0(0%)               2(9%)                    10(42%)             0(0%)         12.04   3.03    26.04   5.00    23.00   /
  Ratnalingam V \[[@R29]\]       2010   Malaysia      non RCT      Vicryl 8-0       60.7/60.7     68            69               3(4.41%)            11(16%)                  0(0%)               0(0%)         16.93   2.85    29.84   5.65    1.00    /
  Rubin MR \[[@R35]\]            2011   Brazil        non RCT      nylon 10-0       45.6/47.8     21            26               1(4.76%)            2(8%)                    1(5%)               1(4%)         19.05   6.12    48.15   7.13    6.00    /
  Yüksel B \[[@R20]\]            2010   Turkey        non RCT      Vicryl 8-0       53.6/54.6     29            29               2(6.9%)             4(14%)                   2(7%)               0(0%)         23.42   13.34   41.45   3.2     21.50   /
  Cha DM \[[@R36]\]              2012   Korea         non RCT      nylon 10--0      63.0/56.9     22            30               1(4.55%)            6(20%)                   18(82%)             16(54%)       27.71   5.22    43.30   8.18    6.00    /
  Küçükerdönmez C \[[@R39]\]     2014   Turkey        non RCT      Vicryl 8-0       57.1/52.1     13            13               0(0%)               0(0%)                    /                   /             /       /       /       /       5.00    /

/: not available; FG: fibrin glue group; SE: suture group; SD: standard deviation.

Recurrence rate, complication rate, and surgical duration {#s2_2}
---------------------------------------------------------

Twenty-three included studies reported the recurrence rate, 17 studies reported the complication rate, and 17 studies compared the surgical duration between FG and suture groups. The pooled odd ratios (ORs) for the recurrence rate and complication rate were 0.35 (95% confidence interval \[CI\]: 0.24--0.51, *P \<* 0.001, I^2^ = 0.0%, Figure [2A](#F2){ref-type="fig"}) under a fixed-effects model and 1.121 (95% CI: 0.540--2.326, *P* = 0.759, I^2^ = 49.0%, Figure [2B](#F2){ref-type="fig"}) under a random-effects model, respectively. The results showed that FG was more effective at reducing the recurrence rate and did not increase the complication rate. The pooled standardized mean difference (SMD) for surgical duration was −4.142 (95% CI: −5.06--3.22, *P \<* 0.001, I^2^ = 95.5%, Figure [2C](#F2){ref-type="fig"}) under the random-effects model. The surgical duration in the FG group was significantly reduced compared with the suture group.

![(**A**) Forest plot of the ORs for the effect of FG versus sutures on the combined outcome "recurrence rate". (**B**) Forest plot of the ORs for the effect of FG versus sutures on the combined outcome "complication rate". (**C**) Forest plot for the effect of FG versus sutures on the combined outcome "surgical duration".](oncotarget-08-41487-g002){#F2}

Stratified analyses {#s2_3}
-------------------

In order to further explore whether FG was associated with the recurrence rate and complication rate, we conducted stratified analysis of recurrence rate and complication rate based on region (Asia and non-Asia), study type (RCT and non-RCT), suture material (vicryl and nylon), sample size (\> 50 eyes and ≤ 50 eyes), follow-up duration (\> 6 months and ≤6 months) and study quality score (≥ 3 and ≤ 2 in RCTs). The ORs are summarized in Table [2](#T2){ref-type="table"}. The stratified analyses did not significantly change the complication rate and recurrence rate results, with the exception that in studies with a quality score of 2 (OR = 3.987, 95% CI: 1.297--12.255, *P* = 0.016, I^2^ = 0.0%), FG significantly increased the complication rate, while in studies with at least a 6 month follow-up duration (OR = 0.49, 95% CI: 0.25--0.98, *P* = 0.043, I^2^ = 0.0%), FG significantly reduced the complication rate. Complications including hemorrhage, dehiscence, inflammation, corneal lesions, and retraction were selected to conduct stratified analyses. The ORs are shown in Table [2](#T2){ref-type="table"}; there was no statistical significance in the sub-group analyses of complication rate, with the exception that the retraction group suggested that FG was associated with an increased retraction rate under the fixed-effects model (OR = 6.398, 95% CI: 1.629--25.125, *P* = 0.008, I^2^ = 0.0%). Due to the lack of studies with a RCT quality score of 2 (*n* = 3), studies with at a least 6 month follow-up duration (*n* = 6), and retraction studies (*n* = 4), further research should be conducted to confirm these findings.

###### Summarized ORs or SMD in this meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Group               Study             Sample size (eye)   OR            95% CI                           *P*                              I^2^ (%)                         Statistical model                            
  ------------------- ----------------- ------------------- ------------- -------------------------------- -------------------------------- -------------------------------- ---------------------- --------------------- --------------
  Main outcomes       Recurrence rate   23                  1680          0.348                            (0.239\~0.506)                   \< 0.001\*                       0.00                   Fixed-effects model   

  Complication rate   17                1234                1.121         (0.540\~2.326)                   0.759                            49.00                            Random-effects model                         

  Surgery time        17                991                 −4.142^a^     (−5.060\~-3.224)                 \< 0.001\*                       95.50                            Random-effects model                         

  Recurrence\         Region            Asia                16/12         934/604                          0.311/1.257                      (0.173\~0.559)/(0.417\~3.786 )   \< 0.001\*/0.684       0/57.9                Fixed/Random
  rate/\                                                                                                                                                                                                                  
  Complication\                                                                                                                                                                                                           
  rate                                                                                                                                                                                                                    

  non-Asia            7/5               746/630             0.38/0.822    (0.233\~0.619)/(0.366-1.849)     \< 0.001\*/0.636                 0/20.8                           Fixed/Random                                 

                                                                                                                                                                                                                          

  Study type          RCT               15/10               915/543       0.344/1.088                      (0.205\~0.578)/(0.385\~3.072)    \< 0.001\*/0.874                 0/45.6                 Fixed/Random          

  non-RCT             8/7               765/691             0.351/1.270   (0.204\~0.604)/(0.385\~4.187)    \< 0.001\*/0.695                 0/60.5                           Fixed/Random                                 

                                                                                                                                                                                                                          

  Suture material     Vicryl            15/11               1299/650      0.351/2.561                      (0.235\~0.525)/(0.556\~11.791)   \< 0.001\*/0.227                 0/70.5                 Fixed/Random          

  Nylon               8/6               381/584             0.326/0.642   (0.115\~0.920)/(0.316\~1.305)    0.034\*/0.221                    0/11.2                           Fixed/Random                                 

                                                                                                                                                                                                                          

  Sample size         \> 50 eyes        11/7                1227/384      0.403/2.492                      (0.180\~0.903)/(0.581\~10.695)   0.027\*/0.059                    0/51.5                 Fixed/Random          

  ≤ 50 eyes           12/10             453/854             0.333/0.602   (0.218\~0.508)/(0.356\~1.019 )   \< 0.001\*/0.219                 0/0                              Fixed/Random                                 

                                                                                                                                                                                                                          

  Follow-up           \> 6 months       11/6                628/365       0.349/0.49                       (0.199\~0.612)/(0.25\~0.98)      \< 0.001\*/0.043                 0/0                    Fixed/Random          

  ≤ 6 months          12/11             1052/869            0.346/2.61    (0.209\~0.573)/(0.80\~8.48)      \< 0.001\*/0.027                 0/57.9                           Fixed/Random                                 

                                                                                                                                                                                                                          

  Quality score       ≥ 3 scores        9/6                 576/349       0.353/0.426                      (0.195\~0.641)/(0.178\~1.018)    0.001\*/0.055                    0/0                    Fixed/Random          

  ≤ 2 scores          6/4               339/194             0.319/3.987   (0.111\~0.916)/(1.297\~12.255)   0.034\*/0.016\*                  0/0                              Fixed/Random                                 

  Complication        Hemorrhage        3                   132           1.575                            (0.532\~4.658)                   0.412                            0.00                   Fixed-effects model   

  Dehiscence          9                 755                 1.068         (0.524\~2.177)                   0.857                            0.00                             Fixed-effects model                          

  Inflammation        9                 801                 1.102         (0.716\~1.696)                   0.658                            33.60                            Fixed-effects model                          

  Corneal lesions     3                 537                 0.543         (0.243\~1.211)                   0.136                            0.00                             Fixed-effects model                          

  Retraction          4                 199                 6.398         (1.629\~25.125)                  0.008\*                          0.00                             Fixed-effects model                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*: statistical significance.

^a^:SMD.

Publication bias {#s2_4}
----------------

There was no publication bias in the recurrence studies (*P* = 0.596, Figure [3A](#F3){ref-type="fig"}), complication rate analysis (*P* = 0.097, Figure [3B](#F3){ref-type="fig"}), or surgical duration analysis (*P* = 0.129, Figure [3C](#F3){ref-type="fig"}).

![(**A**) Funnel plot for the publication bias test in the recurrence studies. (**B**) Funnel plot for the publication bias test in the complication rate analysis. (**C**) Funnel plot for the publication bias test in the surgical duration analysis.](oncotarget-08-41487-g003){#F3}

Sensitivity analysis {#s2_5}
--------------------

To evaluate the stability of results, sensitivity analyses were performed. We removed studies one by one from the analysis; however, the result did not change with the removal of any of the studies, suggesting that our results for the recurrence ([Supplementary Figure 1A](#SD1){ref-type="supplementary-material"}), and surgical duration analysis ([Supplementary Figure 1B](#SD1){ref-type="supplementary-material"}) were consistent. Notably, in the complication rate group ([Supplementary Figure 1C](#SD1){ref-type="supplementary-material"}), after we excluded the study of Hall et al. \[[@R26]\], the I^2^ changed to 34.0%, but the result (OR = 0.90, 95% CI, 0.47--1.70, *P* = 0.118) did not change, suggesting that the results had sufficient statistical power.

Meta-regression analysis {#s2_6}
------------------------

Meta-regression analysis suggested that region, sample size, suture material, and follow up duration did not have a significant impact on the heterogeneity across studies in the recurrence rate group ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). Meta-regression with region, suture material, and follow up duration showed no significant impact on between-study heterogeneity in the complication rate group ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). However, sample size had an impact on the heterogeneity in the complication rate group. Detailed information is shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Trial sequential analysis {#s2_7}
-------------------------

Based on the theory of trial sequential analysis (TSA), in the recurrence group, the required information size to demonstrate a difference in recurrence rate between the FG and suture groups was 6,874 patients (Figure [4A](#F4){ref-type="fig"}). Results showed that the Z-curve crossed the trial monitoring boundary before reaching the required information size, indicating that the cumulative evidence was adequate and further trials were unnecessary. Moreover, the cumulative Z-curve crossed the trial sequential monitoring boundary, establishing sufficient and conclusive evidence in the surgical duration group (Figure [4B](#F4){ref-type="fig"}). However, in the complication group, the Z-curve did not cross the trial monitoring boundary before the required information size was reached (5728 patients), demonstrating that the cumulative evidence was insufficient and more studies were required to confirm this result (Figure [4C](#F4){ref-type="fig"}).

![(**A**) TSA in the recurrence group. (**B**) TSA in surgical duration group. (**C**) TSA in the complication group.](oncotarget-08-41487-g004){#F4}

DISCUSSION {#s3}
==========

We conducted an updated meta-analysis to further explore the association between the application of FG in pterygium surgery, and the recurrence rate, complication rate, and surgical duration. In total, 1,839 eyes from 24 studies were included in the meta-analysis. Based on the overall meta-analysis, we found that, compared with sutures, FG was more effective at reducing the recurrence rate, but not the complication rate. Our analysis indicated a significantly shorter surgical duration for FG compared with sutures. In the subgroup analysis, based on region, follow-up time, quality score, sample size, study type, and suture material, FG still had a lower recurrence rate. Moreover, there were no significant differences in complication rates between the two groups in terms of region, sample size, study type, and suture material. To increase the robustness of this conclusion, we performed a TSA to calculate the required information size and estimate the sample number required to make a stable conclusion.

In the 17 included studies on surgical duration, the use of FG was associated with a markedly reduced surgical time. Vichare et al. \[[@R37]\] showed that the mean surgical durations in the suture and FG groups were 50.93 min and 34.43 min, respectively. Mean surgical duration was also shorter in the FB group (23.42 min) than in the suture group (41.45 min) in another study by Yuksel et al. \[[@R20]\]. As a biological adhesive, when FG is applied to tissue, a firm and stable fibrin network is created and formed in 30 seconds, reproducing the final stage of the coagulation pathway and promoting collagen cross-linking and wound healing \[[@R44]\]. Furthermore, healing after the use of FB is characterized by minimal inflammation, comfortable eye, and good cosmetic outcome compared with sutures \[[@R45]\].

The most important issue for patients and surgeons regarding pterygium surgery is recurrence. In our meta-analysis, 23 trials reported the recurrence rate. Of these studies, five \[[@R13], [@R28], [@R31], [@R39], [@R40]\] reported no recurrence in both groups, which may be related to the short follow-up time. Ratnalingam et al. \[[@R29]\] found no significant difference between suture and FG groups at 1 month and 6 months postoperatively. However, after a 1-year follow-up, three eyes (4.41%) showed recurrence with the presence of fibrovascular tissue crossing the limbus in the 68 eyes in the FB group, which is statistically less than that in the suture group in which 11 recurrences (15.9%) were reported in the 69 eyes that underwent surgery. In our subgroup based on follow-up duration, we found that the recurrence rate in the FG group was lower than that in the suture group at ≥ 6 months and \> 6 months. A possible reason for this difference is that our study had a more adequate sample size. However, the follow-up duration also plays an important role in recurrence time. Furthermore, the recurrence rate in the FG group was still less than that in the suture group in Asian and Non-Asian regions, indicating that FG has stable effect among different ethnicities. Moreover, the result did not change based on other subgroup analyses such as study quality score, study size, study type, and suture material.

Complication rate is another issue concerning pterygium surgery. Four studies \[[@R22], [@R28], [@R29], [@R31]\] did not report any complications in both groups. In the study by Koranyi et al. \[[@R22]\], complications, such as transient transplant edema and persistent corneal epithelial defects, occurred equally in both groups. Meanwhile, Jiang et al. \[[@R23]\] observed no significant differences in the occurrence of other complications between the two groups. Based on our 17 included studies, there was no difference in complication rate between the two groups. Subgroup analysis based on region, sample size, study type, and suture material reached the same conclusion. In the follow-up time of ≤ 6 months group, the FG group had a lower complication rate than the suture group. However, the rate of retraction was higher in the FG group. Hall et al. \[[@R26]\] reported retraction of the nasal edge of the graft in eight patients in the FG group, however, these cases had healed 1 month later and did not present a problem to the patient. Moreover, subgroup analysis based the quality scores in the present study showed a higher complication rate associated with FG use in studies that had a quality score of 2, which may be related to the low quality.

Significant heterogeneity was caused by a combination of different complications in the meta-analysis. Based on sensitive analysis, after we excluded the study of Hall et al. \[[@R26]\], I^2^ changed to 34.0%, but the result remained the same, suggesting that the analysis had sufficient statistical power. Moreover, we used RCTs to obtain more reliable results. Meta-regression indicated that sample size had an impact on the heterogeneity in the complication rate group. Based on our subgroup analysis by sample size in the complication rate group, there was high heterogeneity in the \> 50 eyes group. A possible reason is that this group contained fewer studies (seven studies with 384 eyes).

Our meta-analysis has some limitations that should be acknowledged. First, the number of included studies was insufficient and the included publications were mainly written in English, and relevant studies in other languages may have been omitted. Second, not all included articles were RCTs, so more robust data with greater clinical evidence should be included in future analyses. Third, the relationship between recurrence rate and age was not analyzed due to lack of data. Fourth, the time for recurrence could not be explored due to lack of available data. Finally, only published trials with available data were analyzed in our study; therefore, the inclusion of unpublished data may influence our conclusions.

Based on the 24 included studies, our meta-analysis supports the use of FG for conjunctival autografting in pterygium surgery over sutures. Compared with sutures, FG is more effective at reducing the recurrence rate of pterygium, so patients would benefit from the use of FG. Moreover, there was no difference in complication rate between FG and sutures, indicating that FG has a similar safety compared with sutures. Furthermore, the surgical duration was significantly shorter in the FG group compared with the suture group, decreasing the burden on the medical profession. However, average surgical cost was higher when using FG \[[@R20]\]. In order to reduce the surgical cost, operations should be well-planned. A challenge for clinical practice is that an increasing number of patients are operated on the same day. Therefore, we recommend that doctors communicate well with patients about surgical consumables and expenses. Considering the cost, we recommend suturing for low-income patients.

In conclusion, FG is a safe and effective tool in pterygium surgery with conjunctival limbal autografting. Although there was no difference in the complication rate between FG and sutures, apparent advantages of FG are shorter surgical duration and greater reduction in pterygium recurrence rate. Based on the TSA, these conclusions of recurrence and surgical duration are robust, and further duplicated trials are unnecessary. However, more studies are required to confirm conclusion relating to complication rate.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We conducted an electronic literature search for eligible studies published until July 29, 2016 across multiple databases, including PubMed, Web of Science, Science Direct, Cochrane Central Register of Controlled Trials, Wiley Online Library, China National Knowledge Infrastructure, China Biology Medicine Disc, Chongqing VIP, and Wan Fang Data. The keywords applied in the search were: (pterygium OR pterygia) and conjunctival autograft and suture and (adhesive fibrin tissue OR fibrin adhesive OR fibrin glue OR fibrinogen adhesive OR fibrin sealant system OR autologous fibrin tissue adhesive OR fibrin seal\* OR crosseal OR fibrin klebe system immuno OR transglutine OR human fibrin sealant OR tisseel OR tissel OR tissucol OR beriplast OR FG OR tissue adhesive\* OR biological glue). In addition, previous meta-analyses, review studies, and cited references from relevant articles were screened as appropriate.

Inclusion and exclusion criteria {#s4_2}
--------------------------------

Two authors independently reviewed the titles and abstracts of literature to identify studies which fulfilled the inclusion criteria: (1) clinical trials; (2) patients with primary pterygium; (3) efficacy comparison between FG versus sutures; (4) pterygium surgery with conjunctival limbal autograft; and (5) availability of at least one of the following outcomes: recurrence rate, complication rate, and surgical duration. There were no language restrictions regarding the inclusion of studies. Exclusion criteria comprised the following: (1) patients with recurrent pterygium; (2) pterygium surgery with other autograft; and (3) no available data.

Data extraction and assessment of study quality {#s4_3}
-----------------------------------------------

Two authors independently assessed the quality of the selected trials and extracted the following data: first author\'s name, publication year, country, suture material, mean age, sample size, recurrence rate, complication rate, surgery duration, follow-up duration, and study type. The Jadad composite scale was applied to assess the quality of the included studies, which assigns scores for reported randomization, blinding and withdrawals \[[@R46]\]. The Jadad scale is a 5-point scale, in which a study with a score of ≥ 3 is commonly regarded as high quality and a study with a score of ≤ 2 is low quality \[[@R47]\]. Any disagreement between authors was resolved by discussion to reach consensus.

Statistical analysis {#s4_4}
--------------------

For recurrence rate, we calculated the total number of recurrences at the end of follow-up in all clinical trials. For complication rate, considering the various criteria of complications in the included studies, a uniform standard was established to minimize individual variation among trials. We evaluated all complications with remarkable signs, including the displacement or loss of the autograft, dehiscence, hemorrhage, infection, corneal lesions, and other indications that required special treatment. We excluded common inflammatory reactions, such as edema, fibrosis, and proliferative granuloma, to conduct a stratified analysis. In order to achieve a more accurate analysis of complication rate, hemorrhage, dehiscence, corneal lesions, and retraction were also selected. In addition, we conducted stratified analyses on recurrence rate and complication rate based on region, study type, suture material, sample size, follow-up duration, and study quality score. For the surgical duration, we recorded the mean and standard deviation (SD) from each study. When no SD was available, and the maximum and minimum values were reported, we calculated the SD using the following formula \[[@R25]\]. $\sqrt{\frac{{(Max - Mean)}^{2} + {(Min - Mean)}^{2}}{4}}$ Differences in recurrence rate and complication rate between the FG and suture groups were evaluated by OR with 95% CI, and SMD with 95% CI were used to estimate the difference in surgical duration between groups. We used the I^2^-statistic to calculate heterogeneity among the studies \[[@R48]\], I^2^ \> 50% implies significant heterogeneity resulting in the use of a random-effects model, otherwise a fixed-effects model was selected \[[@R24]\]. Due to the significant heterogeneity caused by a combination of different complications in the meta-analysis, we chosen a random-effects model to investigate complication rate. Publication bias was assessed using funnel plots. Meta-regression analyses assessed the influence of region, sample size, suture material, and follow up duration. All statistical analyses were performed using the STATA (version12.0, STATA Corp., College Station, TX, USA). Statistical significance was determined as *P \<* 0.05.

Trial sequential analysis {#s4_5}
-------------------------

Meta-analyses may result in type I errors owing to an increased risk of random error when the studies included in the meta-analysis have a small sample size, low quality, publication bias, and whose conclusions tend to change by later studies with larger sample sizes \[[@R49]\]. TSA not only allows for controlling the *P-value* when scarce data exist and clear conclusions cannot be drawn, but also allows the quantification of the required sample size for determining the effect whilst adjusting the threshold for statistical significance \[[@R50]\]. Therefore, the required information size was based on the assumption of a plausible relative risk of 30% with low risk bias, and we adopted the risks for a type I error (α) of 5%, and a type II error (β) of 20%. TSA software version 0.9 beta (<http://www.ctu.dk/tsa>) was used in this study. If a TSA monitoring boundary is crossed with the Z-curve before reaching the required information size, robust evidence can be confirmed and further reduplicative studies are unnecessary. Otherwise, it is necessary to continue performing trials \[[@R51]\].

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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